Trieste, Italy

Sara Ferluga

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sara Ferluga

Introduction

Sara Ferluga is a prominent inventor based in Trieste, Italy. She has made significant contributions to the field of cancer treatment through her innovative research and patented inventions. With a total of 3 patents, her work focuses on the development of constructs that target tumors effectively.

Latest Patents

Among her latest patents is a groundbreaking construct that combines an EphA3, EphA2, and/or EphB2 binding ligand with at least one effector molecule. This effector molecule can include a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is designed as a fusion protein or a covalent conjugate. Additionally, she has developed a construct that includes a ligand binding to EphA2, EphA3, and/or EphB2, along with a ligand that binds to IL-13Rα2, and at least one effector molecule. These inventions provide methods for treating cancer, showcasing her commitment to advancing medical science.

Career Highlights

Sara Ferluga is affiliated with Wake Forest University, where she continues her research and development efforts. Her work has garnered attention for its potential impact on cancer therapies, making her a valuable asset in the scientific community.

Collaborations

Sara collaborates with esteemed colleagues such as Waldemar Debinski and Carla Lema Tome. Their combined expertise enhances the research initiatives they undertake, contributing to the advancement of cancer treatment methodologies.

Conclusion

Sara Ferluga's innovative work in cancer treatment through her patented inventions highlights her significant role in the field. Her contributions are paving the way for new therapeutic approaches that could benefit many patients in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…